Hippo-YAP/TAZ pathway regulation: the crucial roles of lncRNAs in cancer

References

• Angus L, Moleirinho S, Herron L, Sinha A, Zhang X, Niestrata M, Dholakia K, Prystowsky MB, Harvey KF, Reynolds PA, et al. 2012. Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Oncogene. 31(2):238–250. doi: 10.1038/onc.2011.224.
   PubMed Web of Science ®Google Scholar
• Aragon E, Goerner N, Xi Q, Gomes T, Gao S, Massague J, Macias MJ. 2012. Structural basis for the versatile interactions of Smad7 with regulator WW domains in TGF-beta pathways. Structure. 20(10):1726–1736. doi: 10.1016/j.str.2012.07.014.
   PubMed Web of Science ®Google Scholar
• Avruch J, Zhou D, Fitamant J, Bardeesy N, Mou F, Barrufet LR. 2012. Protein kinases of the Hippo pathway: regulation and substrates. Semin Cell Dev Biol. 23(7):770–784. doi: 10.1016/j.semcdb.2012.07.002.
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. 2017. Long noncoding RNA and cancer: a New paradigm. Cancer Res. 77(15):3965–3981. doi: 10.1158/0008-5472.CAN-16-2634.
   PubMed Web of Science ®Google Scholar
• Bitra A, Sistla S, Mariam J, Malvi H, Anand R. 2017. Rassf proteins as modulators of Mst1 kinase activity. Sci Rep. 7:45020. doi: 10.1038/srep45020.
   PubMed Web of Science ®Google Scholar
• Calses PC, Crawford JJ, Lill JR, Dey A. 2019. Hippo pathway in cancer: aberrant regulation and therapeutic opportunities. Trends Cancer. 5(5):297–307. doi: 10.1016/j.trecan.2019.04.001.
   PubMed Web of Science ®Google Scholar
• Chae Y, Roh J, Kim W. 2021. The roles played by long non-coding RNAs in glioma resistance. Int J Mol Sci. 22:13.
   Web of Science ®Google Scholar
• Chan JJ, Tay Y. 2018. Noncoding RNA:RNA regulatory networks in cancer. Int J Mol Sci. 19:5.
   Web of Science ®Google Scholar
• Chan LH, Wang W, Yeung W, Deng Y, Yuan P, Mak KK. 2014. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene. 33(40):4857–4866. doi: 10.1038/onc.2013.433.
   PubMed Web of Science ®Google Scholar
• Chen C, Qin L, Xiao MF. 2022. Long noncoding RNA LOC554202 predicts a poor prognosis and correlates with immune infiltration in thyroid cancer. Comput Math Methods Med. 2022:3585626.
   PubMed Web of Science ®Google Scholar
• Chen FB, Wu P, Zhou R, Yang QX, Zhang X, Wang RR, Qi SC, Yang X. 2020. LINC01315 impairs microRNA-211-dependent DLG3 downregulation to inhibit the development of oral squamous cell carcinoma. Front Oncol. 10:556084. doi: 10.3389/fonc.2020.556084.
   PubMed Web of Science ®Google Scholar
• Chen GZ, Zhu HC, Dai WS, Zeng XN, Luo JH, Sun XC. 2017. The mechanisms of radioresistance in esophageal squamous cell carcinoma and current strategies in radiosensitivity. J Thorac Dis. 9(3):849–859. doi: 10.21037/jtd.2017.03.23.
   PubMed Web of Science ®Google Scholar
• Chen K, Wang X, Wei B, Sun R, Wu C, Yang HJ. 2022. LncRNA SNHG6 promotes glycolysis reprogramming in hepatocellular carcinoma by stabilizing the BOP1 protein. Anim Cells Syst. 26(6):369–379. doi: 10.1080/19768354.2022.2134206.
   PubMed Web of Science ®Google Scholar
• Chen W, Wang H, Liu Y, Xu W, Ling C, Li Y, Liu J, Chen M, Zhang Y, Chen B, et al. 2020. Linc-RoR promotes proliferation, migration, and invasion via the Hippo/YAP pathway in pancreatic cancer cells. J Cell Biochem. 121(1):632–641. doi: 10.1002/jcb.29308.
   PubMed Web of Science ®Google Scholar
• Cheng J, Wang S, Dong Y, Yuan Z. 2020. The role and regulatory mechanism of Hippo signaling components in the neuronal system. Front Immunol. 11:281. doi: 10.3389/fimmu.2020.00281.
   PubMed Web of Science ®Google Scholar
• Choi W, Kim J, Park J, Lee DH, Hwang D, Kim JH, Ashktorab H, Smoot D, Kim SY, Choi C, et al. 2018. YAP/TAZ initiates gastric tumorigenesis via upregulation of MYC. Cancer Res. 78(12):3306–3320. doi: 10.1158/0008-5472.CAN-17-3487.
   PubMed Web of Science ®Google Scholar
• Cornils H, Kohler RS, Hergovich A, Hemmings BA. 2011. Downstream of human NDR kinases: impacting on c-myc and p21 protein stability to control cell cycle progression. Cell Cycle. 10(12):1897–1904. doi: 10.4161/cc.10.12.15826.
   PubMed Web of Science ®Google Scholar
• Cunningham R, Hansen CG. 2022. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin Sci. 136(3):197–222. doi: 10.1042/CS20201474.
   Web of Science ®Google Scholar
• Currey L, Thor S, Piper M. 2021. TEAD family transcription factors in development and disease. Development. 148:12. doi: 10.1242/dev.196675.
   Web of Science ®Google Scholar
• de Amorim ISS, de Sousa Rodrigues MM, Mencalha AL. 2021. The tumor suppressor role of salvador family WW domain-containing protein 1 (SAV1): one of the key pieces of the tumor puzzle. J Cancer Res Clin Oncol. 147(5):1287–1297. doi: 10.1007/s00432-021-03552-3.
   PubMed Web of Science ®Google Scholar
• Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, et al. 2012. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 22(9):1775–1789. doi: 10.1101/gr.132159.111.
   PubMed Web of Science ®Google Scholar
• Dey A, Varelas X, Guan KL. 2020. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 19(7):480–494. doi: 10.1038/s41573-020-0070-z.
   PubMed Web of Science ®Google Scholar
• Do H, Kim D, Kang J, Son B, Seo D, Youn H, Youn B, Kim W. 2019. TFAP2C increases cell proliferation by downregulating GADD45B and PMAIP1 in non-small cell lung cancer cells. Biol Res. 52(1):35. doi: 10.1186/s40659-019-0244-5.
   PubMedGoogle Scholar
• Do H, Kim W. 2018. Roles of oncogenic long non-coding RNAs in cancer development. Genomics Inform. 16(4):e18. doi: 10.5808/GI.2018.16.4.e18.
   PubMedGoogle Scholar
• Ehmer U, Sage J. 2016. Control of proliferation and cancer growth by the Hippo signaling pathway. Mol Cancer Res. 14(2):127–140. doi: 10.1158/1541-7786.MCR-15-0305.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al. 2003. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 349(22):2091–2098. doi: 10.1056/NEJMoa031317.
   PubMed Web of Science ®Google Scholar
• Fu M, Hu Y, Lan T, Guan KL, Luo T, Luo M. 2022. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 7(1):376. doi: 10.1038/s41392-022-01191-9.
   PubMed Web of Science ®Google Scholar
• Galan JA, Avruch J. 2016. MST1/MST2 protein kinases: regulation and physiologic roles. Biochemistry. 55(39):5507–5519. doi: 10.1021/acs.biochem.6b00763.
   PubMed Web of Science ®Google Scholar
• Gottesman MM. 2002. Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. doi: 10.1146/annurev.med.53.082901.103929.
   PubMed Web of Science ®Google Scholar
• Guan ZB, Cao YS, Li Y, Tong WN, Zhuo AS. 2018. Knockdown of lncRNA GHET1 suppresses cell proliferation, invasion and LATS1/YAP pathway in non small cell lung cancer. Cancer Biomark. 21(3):557–563. doi: 10.3233/CBM-170431.
   PubMed Web of Science ®Google Scholar
• Gundogdu R, Hergovich A. 2019. MOB (Mps one binder) proteins in the Hippo pathway and cancer. Cells. 8:6. doi: 10.3390/cells8060569.
   Web of Science ®Google Scholar
• Halder G, Johnson RL. 2011. Hippo signaling: growth control and beyond. Development. 138(1):9–22. doi: 10.1242/dev.045500.
   PubMed Web of Science ®Google Scholar
• Han H, Qi R, Zhou JJ, Ta AP, Yang B, Nakaoka HJ, Seo G, Guan KL, Luo R, Wang W. 2018. Regulation of the Hippo pathway by phosphatidic acid-mediated lipid-protein interaction. Mol Cell. 72(2):328–340.e328. doi: 10.1016/j.molcel.2018.08.038.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell. 144(5):646–674. doi: 10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Heng BC, Zhang X, Aubel D, Bai Y, Li X, Wei Y, Fussenegger M, Deng X. 2021. An overview of signaling pathways regulating YAP/TAZ activity. Cell Mol Life Sci. 78(2):497–512. doi: 10.1007/s00018-020-03579-8.
   PubMed Web of Science ®Google Scholar
• Hergovich A, Hemmings BA. 2009. Mammalian NDR/LATS protein kinases in hippo tumor suppressor signaling. Biofactors. 35(4):338–345. doi: 10.1002/biof.47.
   PubMed Web of Science ®Google Scholar
• Hong AW, Meng Z, Plouffe SW, Lin Z, Zhang M, Guan KL. 2020. Critical roles of phosphoinositides and NF2 in Hippo pathway regulation. Genes Dev. 34(7-8):511–525. doi: 10.1101/gad.333435.119.
   PubMed Web of Science ®Google Scholar
• Hu G, Dong B, Zhang J, Zhai W, Xie T, Huang B, Huang C, Yao X, Zheng J, Che J, et al. 2017. The long noncoding RNA HOTAIR activates the Hippo pathway by directly binding to SAV1 in renal cell carcinoma. Oncotarget. 8(35):58654–58667. doi: 10.18632/oncotarget.17414.
   PubMedGoogle Scholar
• Huang Z, Yan Y, Tang P, Cai J, Cao X, Wang Z, Zhang F, Shen B. 2021. TEAD4 as a prognostic marker promotes cell migration and invasion of urinary bladder cancer via EMT. Onco Targets Ther. 14:937–949. doi: 10.2147/OTT.S290425.
   PubMed Web of Science ®Google Scholar
• Huh HD, Kim DH, Jeong HS, Park HW. 2019. Regulation of TEAD transcription factors in cancer biology. Cells. 8:6.
   Web of Science ®Google Scholar
• Hulvat MC. 2020. Cancer incidence and trends. Surg Clin North Am. 100(3):469–481. doi: 10.1016/j.suc.2020.01.002.
   PubMed Web of Science ®Google Scholar
• Kang J, Kim W, Seo H, Kim E, Son B, Lee S, Park G, Jo S, Moon C, Youn H, et al. 2018. Radiation-induced overexpression of transthyretin inhibits retinol-mediated hippocampal neurogenesis. Sci Rep. 8(1):8394. doi: 10.1038/s41598-018-26762-1.
   PubMedGoogle Scholar
• Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, Stadler PF, Hertel J, Hackermuller J, Hofacker IL, et al. 2007. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. 316(5830):1484–1488. doi: 10.1126/science.1138341.
   PubMed Web of Science ®Google Scholar
• Kartal-Yandim M, Adan-Gokbulut A, Baran Y. 2016. Molecular mechanisms of drug resistance and its reversal in cancer. Crit Rev Biotechnol. 36(4):716–726. doi: 10.3109/07388551.2015.1015957.
   PubMed Web of Science ®Google Scholar
• Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, et al. 2018. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 50(12):1705–1715. doi: 10.1038/s41588-018-0252-3.
   PubMed Web of Science ®Google Scholar
• Kim MH, Kim J. 2017. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. Cell Mol Life Sci. 74(8):1457–1474. doi: 10.1007/s00018-016-2412-x.
   PubMed Web of Science ®Google Scholar
• Kim S, Lim SW, Choi J. 2022. Drug discovery inspired by bioactive small molecules from nature. Anim Cells Syst (Seoul). 26(6):254–265. doi: 10.1080/19768354.2022.2157480.
   PubMed Web of Science ®Google Scholar
• Kim W, Jho EH. 2018. The history and regulatory mechanism of the Hippo pathway. BMB Rep. 51(3):106–118. doi: 10.5483/BMBRep.2018.51.3.022.
   PubMed Web of Science ®Google Scholar
• Kim W, Kang J, Lee S, Youn B. 2017. Effects of traditional oriental medicines as anti-cytotoxic agents in radiotherapy. Oncol Lett. 13(6):4593–4601. doi: 10.3892/ol.2017.6042.
   PubMed Web of Science ®Google Scholar
• Kim W, Lee S, Seo D, Kim D, Kim K, Kim E, Kang J, Seong KM, Youn H, Youn B. 2019. Cellular stress responses in radiotherapy. Cells. 8:9.
   Web of Science ®Google Scholar
• Kim W, Son B, Lee S, Do H, Youn B. 2018. Targeting the enzymes involved in arachidonic acid metabolism to improve radiotherapy. Cancer Metastasis Rev. 37(2-3):213–225. doi: 10.1007/s10555-018-9742-0.
   PubMed Web of Science ®Google Scholar
• Kim W, Youn H, Lee S, Kim E, Kim D, Sub Lee J, Lee JM, Youn B. 2018. RNF138-mediated ubiquitination of rpS3 is required for resistance of glioblastoma cells to radiation-induced apoptosis. Exp Mol Med. 50(1):e434. doi: 10.1038/emm.2017.247.
   PubMedGoogle Scholar
• Kontomanolis E N, Syllaios A, Schizas D, Kalagasidou S, Pagkalos A, Alatzidou D, Kantari P, Ntounis T, Fasoulakis Z. 2021. Basic principles of molecular biology of cancer cell-molecular cancer indicators. J Buon. 26(5):1723–1734.
   Google Scholar
• Lamar JM, Xiao Y, Norton E, Jiang ZG, Gerhard GM, Kooner S, Warren JSA, Hynes RO. 2019. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis. J Biol Chem. 294(7):2302–2317. doi: 10.1074/jbc.RA118.004364.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim NH, Cho ES, Yang JH, Cha YH, Kang HE, Yun JS, Cho SB, Lee SH, Paclikova P, et al. 2018. Dishevelled has a YAP nuclear export function in a tumor suppressor context-dependent manner. Nat Commun. 9(1):2301. doi: 10.1038/s41467-018-04757-w.
   PubMedGoogle Scholar
• Li C, Li X. 2022. Antitumor activity of lncRNA NBAT-1 via inhibition of miR-4504 to target to WWC3 in oxaliplatin-resistant colorectal carcinoma. J Healthc Eng. 2022:9121554.
   PubMed Web of Science ®Google Scholar
• Li D, Hu X, Yu S, Deng S, Yan M, Sun F, Song J, Tang L. 2020. Silence of lncRNA MIAT-mediated inhibition of DLG3 promoter methylation suppresses breast cancer progression via the Hippo signaling pathway. Cell Signal. 73:109697. doi: 10.1016/j.cellsig.2020.109697.
   PubMed Web of Science ®Google Scholar
• Li P, Wang J, Zhi L, Cai F. 2021. Linc00887 suppresses tumorigenesis of cervical cancer through regulating the miR-454-3p/FRMD6-Hippo axis. Cancer Cell Int. 21(1):33. doi: 10.1186/s12935-020-01730-w.
   PubMed Web of Science ®Google Scholar
• Li S, Yu Z, Chen SS, Li F, Lei CY, Chen XX, Bao JM, Luo Y, Lin GZ, Pang SY, et al. 2015. The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNA. Urol Oncol. 33(10):427.e1–427.e10.
   PubMed Web of Science ®Google Scholar
• Lin KC, Moroishi T, Meng Z, Jeong HS, Plouffe SW, Sekido Y, Han J, Park HW, Guan KL. 2017. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. Nat Cell Biol. 19(8):996–1002. doi: 10.1038/ncb3581.
   PubMed Web of Science ®Google Scholar
• Liu CY, Chan SW, Guo F, Toloczko A, Cui L, Hong W. 2016. MRTF/SRF dependent transcriptional regulation of TAZ in breast cancer cells. Oncotarget. 7(12):13706–13716. doi: 10.18632/oncotarget.7333.
   PubMedGoogle Scholar
• Liu J, Li J, Li P, Jiang Y, Chen H, Wang R, Cao F, Liu P. 2019. DLG5 suppresses breast cancer stem cell-like characteristics to restore tamoxifen sensitivity by inhibiting TAZ expression. J Cell Mol Med. 23(1):512–521. doi: 10.1111/jcmm.13954.
   PubMed Web of Science ®Google Scholar
• Liu J, Li P, Wang R, Li J, Zhang M, Song Z, Liu P. 2019. High expression of DLG3 is associated with decreased survival from breast cancer. Clin Exp Pharmacol Physiol. 46(10):937–943. doi: 10.1111/1440-1681.13132.
   PubMed Web of Science ®Google Scholar
• Liu X, Fu Q, Bian X, Fu Y, Xin J, Liang N, Li S, Zhao Y, Fang L, Li C, et al. 2020. Long Non-coding RNA MAPK8IP1P2 inhibits lymphatic metastasis of thyroid cancer by activating Hippo signaling via sponging miR-146b-3p. Front Oncol. 10:600927. doi: 10.3389/fonc.2020.600927.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li M, Yu H, Piao H. 2020. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR-125a-5p. Int J Mol Med. 45(2):497–509.
   PubMed Web of Science ®Google Scholar
• Lu X, Wu Y, Cao R, Yu X, Gong J. 2022. CXCL12 secreted by pancreatic stellate cells accelerates gemcitabine resistance of pancreatic cancer by enhancing glycolytic reprogramming. Anim Cells Syst (Seoul). 26(4):148–157. doi: 10.1080/19768354.2022.2091019.
   PubMed Web of Science ®Google Scholar
• Ma S, Meng Z, Chen R, Guan KL. 2019. The Hippo pathway: biology and pathophysiology. Annu Rev Biochem. 88:577–604. doi: 10.1146/annurev-biochem-013118-111829.
   PubMed Web of Science ®Google Scholar
• Meng Z, Moroishi T, Guan KL. 2016. Mechanisms of Hippo pathway regulation. Genes Dev. 30(1):1–17. doi: 10.1101/gad.274027.115.
   PubMed Web of Science ®Google Scholar
• Mercer TR, Dinger ME, Mattick JS. 2009. Long non-coding RNAs: insights into functions. Nat Rev Genet. 10(3):155–159. doi: 10.1038/nrg2521.
   PubMed Web of Science ®Google Scholar
• Misra JR, Irvine KD. 2018. The Hippo signaling network and its biological functions. Annu Rev Genet. 52:65–87. doi: 10.1146/annurev-genet-120417-031621.
   PubMed Web of Science ®Google Scholar
• Mo JS, Park HW, Guan KL. 2014. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 15(6):642–656. doi: 10.15252/embr.201438638.
   PubMed Web of Science ®Google Scholar
• Mohajan S, Jaiswal PK, Vatanmakarian M, Yousefi H, Sankaralingam S, Alahari SK, Koul S, Koul HK. 2021. Hippo pathway: regulation, deregulation and potential therapeutic targets in cancer. Cancer Lett. 507:112–123. doi: 10.1016/j.canlet.2021.03.006.
   PubMed Web of Science ®Google Scholar
• Nan Y, Luo Q, Wu X, Liu S, Zhao P, Chang W, Zhou A, Liu Z. 2022. DLGAP1-AS2-Mediated phosphatidic acid synthesis activates YAP signaling and confers chemoresistance in squamous cell carcinoma. Cancer Res. 82(16):2887–2903. doi: 10.1158/0008-5472.CAN-22-0717.
   PubMed Web of Science ®Google Scholar
• Ni W, Yao S, Zhou Y, Liu Y, Huang P, Zhou A, Liu J, Che L, Li J. 2019. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m(6)A reader YTHDF3. Mol Cancer. 18(1):143. doi: 10.1186/s12943-019-1079-y.
   PubMed Web of Science ®Google Scholar
• Ni W, Zhang Y, Zhan Z, Ye F, Liang Y, Huang J, Chen K, Chen L, Ding Y. 2017. A Novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1. J Hematol Oncol. 10(1):91.
   PubMed Web of Science ®Google Scholar
• Papait R, Kunderfranco P, Stirparo GG, Latronico MV, Condorelli G. 2013. Long noncoding RNA: a new player of heart failure? J Cardiovasc Transl Res. 6(6):876–883. doi: 10.1007/s12265-013-9488-6.
   PubMed Web of Science ®Google Scholar
• Park JH, Pyun WY, Park HW. 2020. Cancer metabolism: phenotype, signaling and therapeutic targets. Cells. 9:10.
   Web of Science ®Google Scholar
• Piccolo S, Dupont S, Cordenonsi M. 2014. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 94(4):1287–1312. doi: 10.1152/physrev.00005.2014.
   PubMed Web of Science ®Google Scholar
• Plouffe SW, Hong AW, Guan KL. 2015. Disease implications of the Hippo/YAP pathway. Trends Mol Med. 21(4):212–222. doi: 10.1016/j.molmed.2015.01.003.
   PubMed Web of Science ®Google Scholar
• Pocaterra A, Romani P, Dupont S. 2020. YAP/TAZ functions and their regulation at a glance. J Cell Sci. 133:2. doi: 10.1242/jcs.230425.
   Web of Science ®Google Scholar
• Roh J, Im M, Chae Y, Kang J, Kim W. 2022. The involvement of long Non-coding RNAs in glutamine-metabolic reprogramming and therapeutic resistance in cancer. Int J Mol Sci. 23:23.
   Web of Science ®Google Scholar
• Roh J, Im M, Kang J, Youn B, Kim W. 2023. Long non-coding RNA in glioma: novel genetic players in temozolomide resistance. Anim Cells Syst (Seoul. 27(1):19–28. doi: 10.1080/19768354.2023.2175497.
   PubMed Web of Science ®Google Scholar
• Roh J, Kim B, Im M, Jang W, Chae Y, Kang J, Youn B, Kim W. 2023. MALAT1-regulated gene expression profiling in lung cancer cell lines. BMC Cancer. 23(1):818. doi: 10.1186/s12885-023-11347-7.
   PubMed Web of Science ®Google Scholar
• Saito A, Nagase T. 2015. Hippo and TGF-beta interplay in the lung field. Am J Physiol Lung Cell Mol Physiol. 309(8):L756–L767. doi: 10.1152/ajplung.00238.2015.
   PubMed Web of Science ®Google Scholar
• Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, et al. 2018. Oncogenic signaling pathways in The cancer genome atlas. Cell. 173(2):321–337.e310. doi: 10.1016/j.cell.2018.03.035.
   PubMed Web of Science ®Google Scholar
• Seo D, Kim D, Chae Y, Kim W. 2020. The ceRNA network of lncRNA and miRNA in lung cancer. Genomics Inform. 18(4):e36. doi: 10.5808/GI.2020.18.4.e36.
   PubMedGoogle Scholar
• Seo D, Kim D, Kim W. 2019. Long non-coding RNA linc00152 acting as a promising oncogene in cancer progression. Genomics Inform. 17(4):e36. doi: 10.5808/GI.2019.17.4.e36.
   PubMedGoogle Scholar
• Seo D, Roh J, Chae Y, Kim W. 2021. Gene expression profiling after LINC00472 overexpression in an NSCLC cell line1. Cancer Biomark. 32(2):175–188. doi: 10.3233/CBM-210242.
   PubMed Web of Science ®Google Scholar
• Seo J, Kim J. 2018. Regulation of Hippo signaling by actin remodeling. BMB Rep. 51(3):151–156. doi: 10.5483/BMBRep.2018.51.3.012.
   PubMed Web of Science ®Google Scholar
• Shen M, Su Y, Song S, Liu D, Liu Z, Chen D, Pan Y, Zhang L, Xu X. 2023. SNHG14 facilitates cell proliferation in colorectal cancer through targeting KRAS via Hippo-YAP signaling. Cell Mol Biol (Noisy-le-Grand). 69(3):64–68. doi: 10.14715/cmb/2023.69.3.8.
   PubMed Web of Science ®Google Scholar
• Shen YW, Zhou YD, Chen HZ, Luan X, Zhang WD. 2021. Targeting CTGF in cancer: an emerging therapeutic opportunity. Trends Cancer. 7(6):511–524. doi: 10.1016/j.trecan.2020.12.001.
   PubMed Web of Science ®Google Scholar
• Shih CH, Chuang LL, Tsai MH, Chen LH, Chuang EY, Lu TP, Lai LC. 2021. Hypoxia-Induced MALAT1 promotes the proliferation and migration of breast cancer cells by sponging MiR-3064-5p. Front Oncol. 11:658151. doi: 10.3389/fonc.2021.658151.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. 2022. Cancer Statistics, 2022. CA Cancer J Clin. 72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Slack FJ, Chinnaiyan AM. 2019. The role of Non-coding RNAs in oncology. Cell. 179(5):1033–1055. doi: 10.1016/j.cell.2019.10.017.
   PubMed Web of Science ®Google Scholar
• Soltani R, Amini M, Mazaheri Moghaddam M, Jebelli A, Ahmadiyan S, Bidar N, Baradaran B, MotieGhader H, Asadi M, Mokhtarzadeh A. 2022. LncRNA DLGAP1-AS2 overexpression associates with gastric tumorigenesis: a promising diagnostic and therapeutic target. Mol Biol Rep. 49(7):6817–6826. doi: 10.1007/s11033-021-07038-w.
   PubMed Web of Science ®Google Scholar
• Son B, Lee S, Youn H, Kim E, Kim W, Youn B. 2017. The role of tumor microenvironment in therapeutic resistance. Oncotarget. 8(3):3933–3945. doi: 10.18632/oncotarget.13907.
   PubMedGoogle Scholar
• Sun W, Shi Q, Zhang H, Yang K, Ke Y, Wang Y, Qiao L. 2019. Advances in the techniques and methodologies of cancer gene therapy. Discov Med. 27(146):45–55.
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Ward EM, Jemal A. 2016. Global cancer incidence and mortality rates and trends–An update. Cancer Epidemiol Biomarkers Prev. 25(1):16–27. doi: 10.1158/1055-9965.EPI-15-0578.
   PubMed Web of Science ®Google Scholar
• Totaro A, Panciera T, Piccolo S. 2018. YAP/TAZ upstream signals and downstream responses. Nat Cell Biol. 20(8):888–899. doi: 10.1038/s41556-018-0142-z.
   PubMed Web of Science ®Google Scholar
• Tu J, Tan X, Chen Y, Chen Y, Li Z, Zhang Y, Chen X, Yang H, Chen H, Yu Z. 2022. Growth arrest-specific transcript 5 represses endometrial cancer development by promoting antitumor function of tumor-associated macrophages. Cancer Sci. 113(8):2496–2512. doi: 10.1111/cas.15390.
   PubMed Web of Science ®Google Scholar
• Vaghari-Tabari M, Ferns GA, Qujeq D, Andevari AN, Sabahi Z, Moein S. 2021. Signaling, metabolism, and cancer: an important relationship for therapeutic intervention. J Cell Physiol. 236(8):5512–5532. doi: 10.1002/jcp.30276.
   PubMed Web of Science ®Google Scholar
• Varelas X. 2014. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development. 141(8):1614–1626. doi: 10.1242/dev.102376.
   PubMed Web of Science ®Google Scholar
• Wang H, Min J, Xu C, Liu Y, Yu Z, Gong A, Xu M. 2023. Hypoxia-elicited exosomes promote the chemoresistance of pancreatic cancer cells by transferring LncROR via hippo signaling. J Cancer. 14(6):1075–1087. doi: 10.7150/jca.81320.
   PubMed Web of Science ®Google Scholar
• Wang J, Huang F, Shi Y, Zhang Q, Xu S, Yao Y, Jiang R. 2021. RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription. Gastric Cancer. 24(1):85–102. doi: 10.1007/s10120-020-01099-9.
   PubMed Web of Science ®Google Scholar
• Wang P, Bai C, Shen S, Jiang C, Deng J, Han D. 2021. MALAT1 promotes malignant pleural mesothelioma by sponging miR-141-3p. Open Med (Wars). 16(1):1653–1667. doi: 10.1515/med-2021-0383.
   PubMedGoogle Scholar
• Wang Y, Jia A, Cao Y, Hu X, Wang Y, Yang Q, Bi Y, Liu G. 2020. Hippo kinases MST1/2 regulate immune cell functions in cancer, infection, and autoimmune diseases. Crit Rev Eukaryot Gene Expr. 30(5):427–442. doi: 10.1615/CritRevEukaryotGeneExpr.2020035775.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu S. 2021. LncRNA GHET1 promotes hypoxia-induced glycolysis, proliferation, and invasion in triple-negative breast cancer through the Hippo/YAP signaling pathway. Front Cell Dev Biol. 9:643515. doi: 10.3389/fcell.2021.643515.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xin D, Zhou L. 2020. LncRNA LINC00152 increases the aggressiveness of human retinoblastoma and enhances carboplatin and Adriamycin resistance by regulating MiR-613/Yes-associated protein 1 (YAP1) axis. Med Sci Monit. 26.
   Web of Science ®Google Scholar
• Wei Y, Hui VLZ, Chen Y, Han R, Han X, Guo Y. 2023. YAP/TAZ: molecular pathway and disease therapy. MedComm. 4(4):e340.
   PubMedGoogle Scholar
• Wennmann DO, Schmitz J, Wehr MC, Krahn MP, Koschmal N, Gromnitza S, Schulze U, Weide T, Chekuri A, Skryabin BV, et al. 2014. Evolutionary and molecular facts link the WWC protein family to Hippo signaling. Mol Biol Evol. 31(7):1710–1723. doi: 10.1093/molbev/msu115.
   PubMed Web of Science ®Google Scholar
• Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG. 1991. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 324(24):1685–1690. doi: 10.1056/NEJM199106133242402.
   PubMed Web of Science ®Google Scholar
• Wu Q, Guo J, Liu Y, Zheng Q, Li X, Wu C, Fang D, Chen X, Ma L, Xu P, et al. 2021. YAP drives fate conversion and chemoresistance of small cell lung cancer. Sci Adv. 7(40):eabg1850.
   PubMed Web of Science ®Google Scholar
• Wu X, Wang Y, Zhong W, Cheng H, Tian Z. 2020. The long Non-coding RNA MALAT1 enhances ovarian cancer cell stemness by inhibiting YAP translocation from nucleus to cytoplasm. Med Sci Monit. 26:e922012.
   PubMed Web of Science ®Google Scholar
• Xiao L, Shi XY, Li ZL, Li M, Zhang MM, Yan SJ, Wei ZL. 2021. Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway. J Gynecol Oncol. 32(5):e77. doi: 10.3802/jgo.2021.32.e77.
   PubMed Web of Science ®Google Scholar
• Xie SC, Zhang JQ, Jiang XL, Hua YY, Xie SW, Qin YA, Yang YJ. 2020. LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma. Cell Death Dis. 11(8):676. doi: 10.1038/s41419-020-02853-8.
   PubMed Web of Science ®Google Scholar
• Yang P, Zhang D, Wang T, Ji J, Jin C, Peng C, Tan Y, Zhou J, Wang L, Feng Y, et al. 2022. CAF-derived exosomal WEE2-AS1 facilitates colorectal cancer progression via promoting degradation of MOB1A to inhibit the Hippo pathway. Cell Death Dis. 13(9):796. doi: 10.1038/s41419-022-05240-7.
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu X, Zheng J, Xue Y, Liu L, Ma J, Wang P, Yang C, Wang D, Shao L, et al. 2020. Interaction of BACH2 with FUS promotes malignant progression of glioma cells via the TSLNC8-miR-10b-5p-WWC3 pathway. Mol Oncol. 14(11):2936–2959. doi: 10.1002/1878-0261.12795.
   PubMed Web of Science ®Google Scholar
• Yao PA, Wu Y, Zhao K, Li Y, Cao J, Xing C. 2022. The feedback loop of ANKHD1/lncRNA MALAT1/YAP1 strengthens the radioresistance of CRC by activating YAP1/AKT signaling. Cell Death Dis. 13(2):103. doi: 10.1038/s41419-022-04554-w.
   PubMed Web of Science ®Google Scholar
• Yao RW, Wang Y, Chen LL. 2019. Cellular functions of long noncoding RNAs. Nat Cell Biol. 21(5):542–551. doi: 10.1038/s41556-019-0311-8.
   PubMed Web of Science ®Google Scholar
• Yeung KT, Yang J. 2017. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 11(1):28–39. doi: 10.1002/1878-0261.12017.
   PubMed Web of Science ®Google Scholar
• Yu M, Shi C, Xu D, Lin X, Ji T, Shi Z, Zhuge X, Zhuo S, Yang Q. 2022. LncRNA ASB16-AS1 drives proliferation, migration, and invasion of colorectal cancer cells through regulating miR-185-5p/TEAD1 axis. Cell Cycle. 21(1):1–11. doi: 10.1080/15384101.2021.1973700.
   PubMed Web of Science ®Google Scholar
• Yue X, Wu WY, Dong M, Guo M. 2021. LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570-3p. Biomed J. 44(6 Suppl 2):S296–S304.
   Web of Science ®Google Scholar
• Zanconato F, Cordenonsi M, Piccolo S. 2016. YAP/TAZ at the roots of cancer. Cancer Cell. 29(6):783–803. doi: 10.1016/j.ccell.2016.05.005.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Qiu N, Yin J, Zhang J, Liu H, Guo W, Liu M, Liu T, Chen D, Luo K, et al. 2020. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression. Theranostics. 10(10):4290–4307. doi: 10.7150/thno.41008.
   PubMed Web of Science ®Google Scholar
• Zheng L, Luo C, Yang N, Pei H, Ji M, Shu Y, Zhang Z, Dong S, Wang X, Li X, et al. 2022. Ionizing radiation-induced long noncoding RNA CRYBG3 regulates YAP/TAZ through mechanotransduction. Cell Death Dis. 13(3):209. doi: 10.1038/s41419-022-04650-x.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Jin Q, Chang J, Zhao Z, Sun C. 2022. Correction to: long non-coding RNA ZMIZ1-AS1 promotes osteosarcoma progression by stabilization of ZMIZ1. Cell Biol Toxicol.
   Web of Science ®Google Scholar
• Zhu B, Finch-Edmondson M, Leong KW, Zhang X VM, Lin QXX, Lee Y, Ng WT, Guo H, Wan Y, et al. 2021. LncRNA SFTA1P mediates positive feedback regulation of the Hippo-YAP/TAZ signaling pathway in non-small cell lung cancer. Cell Death Discov. 7:1.
   Web of Science ®Google Scholar
• Zhu Y, Bo H, Chen Z, Li J, He D, Xiao M, Xiang L, Jin L, Zhou J, Gong L, et al. 2020. LINC00968 can inhibit the progression of lung adenocarcinoma through the miR-21-5p/SMAD7 signal axis. Aging. 12(21):21904–21922.
   PubMedGoogle Scholar
• Zhuang C, Liu Y, Fu S, Yuan C, Luo J, Huang X, Yang W, Xie W, Zhuang C. 2020. Silencing of lncRNA MIR497HG via CRISPR/Cas13d induces bladder cancer progression through promoting the crosstalk between Hippo/Yap and TGF-beta/smad signaling. Front Mol Biosci. 7:616768. doi: 10.3389/fmolb.2020.616768.
   PubMed Web of Science ®Google Scholar
• Zhuang C, Liu Y, Fu S, Yuan C, Luo J, Huang X, Yang W, Xie W, Zhuang C. 2021. Corrigendum: silencing of lncRNA MIR497HG via CRISPR/Cas13d induces bladder cancer progression through promoting the crosstalk between Hippo/Yap and TGF-beta/smad signaling. Front Mol Biosci. 8:664616. doi: 10.3389/fmolb.2021.664616.
   PubMed Web of Science ®Google Scholar
• Zhuo H, Wu C, Tang J, Zhang F, Xu Z, Sun D, Teng Y, Tan Z. 2023. RP11-40C6.2 inactivates Hippo signaling by attenuating YAP1 ubiquitylation in hepatitis B virus-associated hepatocellular carcinoma. J Clin Transl Hepatol. 11(2):323–333.
   PubMed Web of Science ®Google Scholar
• Zinatizadeh MR, Miri SR, Zarandi PK, Chalbatani GM, Raposo C, Mirzaei HR, Akbari ME, Mahmoodzadeh H. 2021. The Hippo tumor suppressor pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis. Genes Dis. 8(1):48–60. doi: 10.1016/j.gendis.2019.11.003.
   PubMed Web of Science ®Google Scholar